BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fujifilm Diosynth Biotechnologies Expands R&D Capabilities at its Billingham, UK Site


3/30/2012 10:13:24 AM

Billingham, UK / Morrisville, NC, USA - March 29, 2012: Fujifilm Diosynth Biotechnologies has completed the first phase of a ?3m ($4.5m) investment in new equipment and laboratories at its Billingham, UK site. This expansion reinforces the commitment to lead the global Biologics CMO industry through continuous innovation and implementation of new technologies, service delivery and quality, as announced by Japan-based parent company, FUJIFILM Corporation.

The investment includes a complete refurbishment of its microbial fermentation laboratory, which has been totally refitted, including 8 new in-situ sterilisable 20L Sartorius Stedim Biotech fermenters, and a number of fully-instrumented DASGIP parallel bench-top high-throughput units.

In addition, a new suite of research and development laboratories has been installed for process development work, with a corresponding increase in the company's R&D workforce by 50 to over 150 in the last 12 months to support its growing business. The company expects to further add to this over the coming year at both its Billingham and North Carolina sites.

Mark Carver, PhD, Senior Vice President Research, Development & Innovation said "this investment is in response to our growing innovation activity and to increasing demand from customers for our expertise fast-track development of cost-effective processes for the manufacture of biologics. We are committed to continue to develop leading technology which will deliver benefits to our customers and their patients".



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES